467 related articles for article (PubMed ID: 26596920)
1. Medical Therapy for Inflammatory Bowel Disease.
Grevenitis P; Thomas A; Lodhia N
Surg Clin North Am; 2015 Dec; 95(6):1159-82, vi. PubMed ID: 26596920
[TBL] [Abstract][Full Text] [Related]
2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
3. Heading back to the trough (levels of biologics in IBD).
Hanauer SB
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):548-51. PubMed ID: 25311382
[No Abstract] [Full Text] [Related]
4. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
5. Medical Management of Inflammatory Bowel Disease.
Rahman S; Patel RK; Boden E; Tsikitis VL
Surg Clin North Am; 2024 Jun; 104(3):657-671. PubMed ID: 38677828
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
7. Definition and evaluation of mucosal healing in clinical practice.
Mazzuoli S; Guglielmi FW; Antonelli E; Salemme M; Bassotti G; Villanacci V
Dig Liver Dis; 2013 Dec; 45(12):969-77. PubMed ID: 23932331
[TBL] [Abstract][Full Text] [Related]
8. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
9. Conventional drug therapy for inflammatory bowel disease.
Bryant RV; Brain O; Travis SP
Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
11. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium.
Moffatt DC; Bernstein CN
Best Pract Res Clin Gastroenterol; 2007; 21(5):835-47. PubMed ID: 17889811
[TBL] [Abstract][Full Text] [Related]
12. Evolving treatment strategies for inflammatory bowel disease.
Hanauer SB; Dassopoulos T
Annu Rev Med; 2001; 52():299-318. PubMed ID: 11160781
[TBL] [Abstract][Full Text] [Related]
13. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
Park SH; Aniwan S; Loftus EV
Curr Opin Pharmacol; 2017 Dec; 37():65-71. PubMed ID: 28992449
[TBL] [Abstract][Full Text] [Related]
14. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?].
Gomollón F; Gisbert JP
Gastroenterol Hepatol; 2010 Jan; 33(1):43-53. PubMed ID: 19616870
[TBL] [Abstract][Full Text] [Related]
15. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective.
Allen PB; Bonovas S; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Feb; 20(2):151-161. PubMed ID: 31815548
[No Abstract] [Full Text] [Related]
16. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
17. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
Papi C; Fascì-Spurio F; Rogai F; Settesoldi A; Margagnoni G; Annese V
Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
[TBL] [Abstract][Full Text] [Related]
18. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
19. Management consensus of inflammatory bowel disease for the Asia-Pacific region.
Ouyang Q; Tandon R; Goh KL; Pan GZ; Fock KM; Fiocchi C; Lam SK; Xiao SD
J Gastroenterol Hepatol; 2006 Dec; 21(12):1772-82. PubMed ID: 17074013
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease therapy: current state-of-the-art.
Blonski W; Buchner AM; Lichtenstein GR
Curr Opin Gastroenterol; 2011 Jul; 27(4):346-57. PubMed ID: 21654383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
